Encouraging early safety and biomarker data from uniQure’s gene therapy candidate, AMT-130, for Huntington’s disease have lifted hopes of progress against the disease.
The readout from 10 patients in the low-dose cohort of an ongoing Phase I/II trial in patients with early-stage Huntington’s...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
